BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12197309)

  • 1. Recent advances in the development of gamma-secretase inhibitors.
    Josien H
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
    Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
    Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartic proteases involved in Alzheimer's disease.
    Schmidt B
    Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 8. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
    Jelley RA; Elliott J; Gibson KR; Harrison T; Beher D; Clarke EE; Lewis HD; Shearman M; Wrigley JD
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3839-42. PubMed ID: 16682202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase.
    Middendorp O; Lüthi U; Hausch F; Barberis A
    Biol Chem; 2004 Jun; 385(6):481-5. PubMed ID: 15255179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease.
    Vardy ER; Catto AJ; Hooper NM
    Trends Mol Med; 2005 Oct; 11(10):464-72. PubMed ID: 16153892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid inhibitors and Alzheimer's disease.
    Xia W
    Curr Opin Investig Drugs; 2003 Jan; 4(1):55-9. PubMed ID: 12625030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity.
    Wolfe MS; Citron M; Diehl TS; Xia W; Donkor IO; Selkoe DJ
    J Med Chem; 1998 Jan; 41(1):6-9. PubMed ID: 9438016
    [No Abstract]   [Full Text] [Related]  

  • 14. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-secretase as a target for the treatment of Alzheimer's disease.
    Citron M
    J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in gamma-secretase modulation.
    Pissarnitski D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Fused cyclohexyl sulfones as gamma-secretase inhibitors.
    Shaw D; Best J; Dinnell K; Nadin A; Shearman M; Pattison C; Peachey J; Reilly M; Williams B; Wrigley J; Harrison T
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3073-7. PubMed ID: 16617016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.